Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZ/su vaccine long-term follow-up and additional doses in older adults
NCT02723773Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2016
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 18
01
Overview
Phase 3, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (4 arms), sponsored by GSK. Primary endpoint: Number of Participants Having at Least One Confirmed Herpes Zoster Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall at 72 months. Started Apr 2016; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT02723773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723773.